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ABSTRACT 
Bone marrow is the site of origin of diverse population of hematological cells with lineage 
specific function. The different lineages of cells originate from a common progenitor that has 
a strong self-renewable capability giving rise to myeloid and lymphoid progenitor cells. The 
myeloid progenitor cells terminally differentiate to monocytes, granulocytes, erythrocytes and 
thrombocytes, while the lymphoid progenitor cells terminally differentiate to B, T and NK 
cells. A plethora of extracellular and intracellular factors in a complex yet tightly regulated 
orchestra controls the genesis and function of each cell type. However, breakdown of one or 
more regulatory processes can steer cells towards becoming cancerous, characterized by the 
loss of normal cellular functions and/or morphology. This thesis analyses; The contribution of 
p53 in the regulation of normal T cell homeostasis; A mechanism evolved by EBV for its 
sustenance in B cells and, a mechanism contributing to the development/survival of 
malignant hematopoietic cells. 
The first half of the thesis describes the contribution of the tumor suppressor p53 in the 
regulation of T cell homeostasis. Paper I demonstrates the regulation of pro-apoptotic SAP by 
p53 in activated T cells. p53 and SAP were upregulated in activated but not in unstimulated T 
cells. To determine the effect of p53 on SAP expression, p53 was selectively induced by 
nutlin-3 in unstimulated T cells. This induced SAP mRNA and protein expression. Further, 
chromatin immuno-precipitation confirmed the binding of p53 to the SAP promoter in 
activated T cells. Paper II demonstrated the cMyc-p53 feedback mechanism contributing to T 
cell homeostasis. cMyc, p53 and p14ARF expression was induced in activated T cells. 
Further elevation of p53 in activated T cells by nutlin-3 treatment decreased cell proliferation, 
cMyc and p14ARF expression. At the other end of the feedback loop, inhibition of Notch 
(DAPT) signaling or cMyc (10058-F4) in activated primary T cells decreased proliferation 
accompanied by decreased cMyc, p14ARF and p53 expression. Thus, inhibition of cMyc 
expression had a negative outcome on p53 expression, and induction of p53 had a negative 
consequence on cMyc expression in activated T cells. Nutlin-3 induced p53 and 10058-F4 
mediated cMyc inhibition in activated T cells had a combined effect of apoptosis and cell 
cycle arrest. On the contrary, activated T cells treated with nutlin-3 or cMyc inhibitor (10058-
F4) retained the cytotoxic function despite the diminished proliferation. 
The second half of the thesis explores mechanisms that virus infected and tumor cells exploit 
for their manifestation. In paper III we studied the role of CD4+T cells in the establishment 
and regulation of EBV latency. Our results showed that activated CD4+T cells from healthy 
donors downregulated the latency III protein EBNA2 (and its transcript, Cp) in LCLs, thus 
indicating that they induce a shift in latency towards II. By exploiting the transwell system 
we demonstrated that cell-cell contact is not essential to induce the latency shift, and that 
soluble factors produced by activated CD4+ T cells contributed to this effect. We also 
identified two soluble factors, IL21 and soluble CD40L that facilitates the latency shift. 
In paper IV we analyzed the effects of IFNγ on BCL6 expression in chronic myeloid 
leukemia and multiple myeloma cells. IFNγ or imatinib treatment alone marginally induced 
BCL6 expression in CML cell lines and primary CML stem cells. On the contrary, combined 
treatment with IFNγ and imatinib induced remarkable BCL6 induction in a direct, STAT1 
dependent manner. We also demonstrated that the sustained STAT5 activation is responsible 
for the low BCL6 expression in IFNγ only treated CML cells. IFNγ treatment alone in MM 
cells strongly induced BCL6 expression through STAT1 signaling. Interestingly, IFNα only 
marginally upregulated BCL6 in MM cells in spite of the strong STAT1 and STAT3 
activation. We show that this effect is consequence of the concomitant IFNα induced 
phosphorylation of STAT5. Our finding regarding BCL6 upregulation, elucidates the adverse 
effect of IFNγ on the outcome of tyrosine kinase inhibitor therapy in CML. Furthermore, this 
may partially explain the inefficient therapeutic effects of IFNγ in MM. 
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1 INTRODUCTION 
1.1 Cancer 
Cancer is a generic terminology for a large group of diseases manifested by abnormal 
division or proliferation of cells. The diseased cells - tumor cells can originate from almost all 
tissue types in humans and are different from the normal cells in one or more ways like, 
function and appearance. Genetic alteration is the fundamental requirement but most often 
does not by itself initiate tumor. Exposure to harmful radiations, genotoxic substances and 
viral infections are a few examples that can induce genetic alterations such as mutations, 
deletions or amplifications. Normally, cells with genetic alterations or cells infected by virus 
are eliminated by ‘self-induced’ cell death – apoptosis, or killed by immune cells following 
its recognition - immune surveillance [1], but tumor cells are capable of bypassing such 
regulations. Hallmark capabilities of tumor cells to bypass such processes are summarized by 
Hanahan and Weinberg as follows [2]. (i) Uncontrolled and sustained cell proliferation. (ii) 
Evasion of extra cellular signals that suppress cellular growth. (iii) Avoiding recognition and 
thus elimination by immune cells. (iv) Resistance to programed cell death. (v) Potential for 
unlimited replication, leading to immortality. (vi) Ability to procure nutrition by stimulating 
the formation of new blood vessels. (vii) Alter cellular metabolism to suite high energy and 
cellular substrate requirement. (viii) Loss of anchorage and increased invasiveness that helps 
cell metastasis. (ix) Increased genomic instability and accumulation of mutations. (x) Ability 
to induce inflammatory responses that helps cell proliferation by providing the necessary 
growth signals. 
Genetic alterations in broadly two groups of genes contribute to the pathogenesis of tumors: 
(i) Proto-oncogenes: Those that manifest tumor development and progression. Example: The 
translocation of proto-oncogene cMyc, renders it the oncogenic property and as a 
consequence drives B cell proliferation in Burkitt lymphoma [3] (ii) Tumor suppressor genes: 
Example: p53, the most studied gene is also the most common gene mutated in about half of 
all cancer types [4]. Mutation or deletion of p53 abrogates its ability to induce cell cycle 
arrest, induce cell death by apoptosis and other less understood mechanisms that are essential 
in response to oncogenic stress or DNA damage. 
According to a recent report by World Health Organization (WHO), cancer causes an 
estimated 13% of the deaths worldwide, with a 70% increase in new cancer cases expected in 
the next twenty years, making it a high priority to find long lasting cure for the disease. 
1.2 Tumor suppressor p53 
p53 was discovered by David Lane and Arnold Levine while studying tumor inducing SV40 
viral oncoproteins in mouse cells where it was recognized as a 53 and 54 kDa protein 
respectively in complex with the SV40 large T-antigen [5, 6]. The tumor suppressor role of 
p53 was realized much later in studies comparing the effect of expressing wild type and 
mutant p53 cDNA in transformed rat embryo fibroblasts [7]. The loss of p53 function, either 
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by gene mutations/deletion or by the physical interaction of viral proteins such as, human 
papilloma virus (HPV) protein E6 [8], Human T-lymphotropic virus (HTLV) Type I – Tax 
protein [9] Epstein-Barr virus (EBV) – EBNA-5, -6 and BZLF1 [10-12], renders the cell 
more vulnerable to oncogenic stress induced tumor development. Studies on whole genome 
sequencing confirm that p53 is the most commonly mutated gene spanning all cancer types, 
with a 42% mutation frequency across 12 common types of tumors and above 90% frequency 
in certain high grade tumors [4]. p53 is activated in response to DNA damage by oncogene 
activation and aberrant DNA replication which leads to a selection pressure for p53 mutations 
during tumor development [13, 14] . Numerous findings imply that sustained p53 function is 
essential to regulate cell proliferation and for the prevention of cancer. 
1.2.1 Regulation of p53 
p53 plays a critical role in regulating cell cycle progression and apoptosis. However, 
undesired elevated p53 levels can inhibit normal cellular growth, making it important to 
regulate its expression. In most cell types p53 expression is negatively regulated at the protein 
level by proteasomal degradation. MDM2 is the principal E3-ligase that binds to p53, 
ubiqitinating it for proteasomal degradation [15]. Six lysine residues at the carboxyl terminal 
of p53 are the predominant sites for MDM2 facilitated ubiquitinalation [16]. Apart from 
MDM2, other ubiquitin ligase such as Pirh2, COP1, Arf-BP1 and RNF3 [17-19] have also 
been shown to promote p53 degradation trough ubiqitination. 
p53 is induced as response to various types of cellular stress like oncogenic stress, DNA 
damage, hypoxia, nutrient depravation, telomere attrition and high levels of reactive oxygen 
or nitric oxide. Posttranslational modification of p53 is one of the mechanisms to elevate p53 
level.  Phosphorylation of p53 is often described as the crucial step towards p53 protein 
stabilization [20]. Eleven serine residues in the transactivation domain at the amino terminal 
of p53 are shown to be important sites for phosphorylation leading to the dissociation of the 
MDM2-p53 complex, thus stabilizing p53 protein. In response to cellular stress signals, a 
broad range of kinases such as, ATM, ATR and Chk1/2 are responsible for the 
phosphorylation of multiple serine residues on p53 [21-24]. In addition to phosphorylation, 
p53 can also be acetylated resulting in the destabilization of the MDM2-p53 complex [25]. 
Acetylation of p53 is brought about predominately by CBP/p300 acetyltransferases on the 
carboxyl terminal lysine residues of p53 [26]. 
p53 is also subjected to additional post translational modifications such as, methylation [27], 
sumoylation [28] and neddylation. These modifications of p53 contribute to its 
transactivation function and promoter specificity. A specific combination of posttranslational 
modification of p53 may result in the transactivation of a specific p53 target gene. For 
example, methylation of lysine (K372) by methyltransferase Set7/9 promotes p53 activity, in 
particular the transactivation of p21 [29]. p53 modifications by SUMO and Nedd8 also occur 
on its carboxylic terminal. SUMOylation of p53 contributes to its transcriptional activity [28]. 
Regulation of cell cycle and apoptosis are the primary functions of p53, functions that are 
achieved through its various transcriptional target genes. 
  3 
1.2.2 Cell cycle arrest 
Cellular stress signals that activate p53 pathway transduce signals predominantly culminating 
in cell cycle arrest or apoptosis. The choice made between the two does not entirely rest upon 
p53, but the many variables such as, the type of stress signal and the cellular background, 
which includes co-factors necessary for the initiation of transcriptional of p53 target genes. 
The ratio between expression levels of pro-apoptotic and pro-survival cellular proteins is also 
a deciding factor between cell survival (cell cycle arrest) and death (apoptosis). 
Replication of DNA and retaining its integrity is fundament for a successful cell division. The 
events leading to DNA replication for the generation of two daughter cells are grouped into 
different stages, 
G0 phase - Cells have exited cell cycle and do not divide 
G1 phase - Checkpoint phase where cells are committed/prepared to enter cell cycle 
S phase - DNA synthesis/replication phase 
G2 phase - Checkpoint phase where cells continue to grow and prepare for cell division 
M phase - Nuclear division, followed by cellular division resulting in two daughter cells 
Cell cycle checkpoints are mechanisms that ensure the timing of various events related to 
DNA replication during cell division. Cyclins in complexes with Cyclin Dependent Kinases 
(CDKs) regulate the progression of cell cycle. p53 induced cell cycle arrest is primarily 
through its well established transcriptional target p21 (WAF1/CIP1) [30], that induces arrest 
of cells in the G0/G1 or the G2 phase cell cycle [31]. p21 is a CDK inhibitor which by 
forming a complex with CDK1 or CDK2 is able to induce arrest of cells in G0/G1 or the G2 
phase of cell cycle [32, 33]. 
Another pathway leading to cell cycle arrest as a response to DNA damage is through p53 
induced 14-3-3-sigma that leads to the arrest of cells in the pre mitotic (G2/M) phase of cell 
cycle [34]. DNA damage induced in human colorectal cancer cells lacking 14-3-3-sigma was 
only briefly able to exit cell cycle, whereas those expressing the protein were arrested in the 
G2/M phase. The inability to sequester CyclinB1/cdc2 complex as they lacked 14-3-3-sigma 
allowed these cells to enter mitosis resulting in death, referred to as ‘mitotic catastrophe’[35]. 
Ectopic expression of 14-3-3-sigma in colorectal cancer cell lines resulted in cell cycle arrest 
in the G2 phase, with DNA content of 4N. However, prolonged expression of 14-3-3sigma in 
these cells resulted in polyploidy [34]. 
In addition to DNA damage response, p53 is also activated in response to limited availability 
of nutrients or a deregulated pathway sensing the availability of nutrients. Under normal 
conditions of adequate glucose and amino acids levels, signals through the IGF-
1/AKT/mTOR pathways allow cell growth and division. However, when cells are under 
nutritional stress, they undergo senescence or quiescence. Prolonged nutrient deprivation can 
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also lead to cell death. Through modulating the expression of IGF-BP3, PTEN, TSC2, 
AMPK b1, Sestrins1/2 and REDD1 by p53, the IGF-1/AKT/mTOR pathways are negatively 
regulated, thus altering cellular metabolism [36]. 
1.2.3 Apoptosis 
The mechanism of cell death by apoptosis was discovered while studying the early 
development of the organism, Caenorhabditis elegans [37]. The organism develops from an 
initial 1090 somatic cells, of which 131 cells undergo ‘programed cell death’ at specific time 
points during the course of development. The invariant number and time of cell death during 
the course of development of the worms was realized to be vital for the development of the 
organism. 
The tumor suppressor function of p53 is to maintain tissue homeostasis, controlling the 
number of cells in a particular tissue/organ system. Prevention of the aberrant proliferation of 
cells is one of the regulatory mechanisms of establishing homeostasis. Another crucial way of 
maintaining homeostasis is through the regulation of cell number through a well 
choreographed mechanism of programmed cell death – apoptosis [38]. Loss of p53 function 
has been associated with about half of the cancer incidences, providing cancer cells with the 
advantage of impaired apoptosis following cellular stress signals. Cell death through 
apoptosis follows a well orchestrated sequential mechanism elicited through a number of 
molecular pathways, the most characterized and prominent of which are the extrinsic/death 
receptor pathway and the intrinsic/mitochondrial pathways. 
Cells that receive signals for apoptosis undergo certain fundamental biochemical changes that 
contribute to programmed cell death. The proteolytic cleavage of caspases, which in normal 
cells are expressed as inactive proenzymes is one of the important changes in cells 
undergoing apoptosis. Proteolytic cleavage of the proenzyme to form active caspases 
amplifies the apoptotic signaling pathway leading to the rapid death of cells. Caspases 
themselves have proteolytic activity, sequentially cleaving other caspases and culminating 
with the fragmentation of DNA and eventually death [39]. 
1.2.3.1 Extrinsic pathway of apoptosis 
The cell in this case receives extracellular signal to initiate apoptosis. The extracellular 
domains of ‘death receptors’ are the docking sites for the death signal (ligand) to be 
transmitted to the intracellular components triggering a cascade of events leading to cellular 
death. FasL/Fas, Apo3L/DR3, Apo2L/DR4, Apo2L/DR5 and TNFa/TNFR1 are well 
characterized pairs of ligands and their corresponding death receptors [40-43]. The 
mechanism of extrinsic apoptotic pathway has been well defined in the FasL/Fas model. As a 
first step, Fas trimerises following the binding of it by the FasL, initiating the downstream 
apoptotic machinery. The Fas associated protein with death domain (FADD), an adaptor 
protein is recruited to the cytoplasmic death domain of the Fas receptor. Consequently, 
FADD recruits procaspase 8, bridging Fas and procaspase 8 to form the death inducing 
signaling complex (DISC). The formation of the DISC domain results in the autocatalytic 
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activation of procaspase 8 [40]. With the activation of caspase 8, execution phase of 
apoptosis is triggered. 
1.2.3.2 Intrinsic pathway of apoptosis 
Non-receptor mediated apoptotic stimuli target molecules in the cell that are associated with 
the destabilization of the mitochondria.  Stimuli for intrinsic pathway may oppose cell 
survival or favor apoptosis. Deprivation of nutrition, growth factor and cytokines are negative 
signals that breakdown cell survival programs. On the contrary, positive signals that favour 
apoptosis are stimuli associated with DNA damage, hypoxia, toxins, free radicals and 
infectious agents. These stimuli destabilize the mitochondrial trans-membrane potential 
leading to the release of caspase activating proteins into the cytoplasm. This early phase of 
apoptosis leads to the formation of ‘apoptosome’, a complex formed between the cytochrome 
c released from the inner wall of the mitochondria, procaspase-9 and Apaf-1 [44]. 
Cells have mechanisms to counter act apoptosis initiated through the intrinsic pathway. 
Inhibitors of apoptosis proteins (IAP) are pro-survival proteins that block the function of 
caspases [45]. However, IAPs can also be inhibited through the formation of complexes with 
the pro-apoptotic Smac and HtrA2, also released from the mitochondria after pro-apoptotic 
stimuli, allowing caspases to amplify the downstream apoptotic signals [46, 47]. Following 
release of cyt c from the mitochondria, apoptosis inducing factor (AIF), caspase activated 
DNAs (CAD) and endonuclease - proteins that are responsible for DNA condensation and 
fragmentation are also released [48]. 
Bcl-2 family of proteins regulate the events leading to apoptosis involving mitochondria [49]. 
The Bcl-2 family consists of both pro-survival/anti-apoptotic and pro-apoptotic proteins. By 
regulating the expression of Bax - a member of Bcl-2 family of proteins, p53 plays a critical 
role in the induction of apoptosis through the mitochondrial pathway [50, 51]. p53 also 
positively regulates the expression pro-apoptotic Puma, Noxa and Bid - members of ‘BH3 
only’ class of Bcl-2 family proteins. The BH3-only proteins act upstream of Bax and 
facilitate the destabilization of the mitochondrial membrane potential to induce apoptosis. In 
addition, p53 can control apoptosis involving mitochondria in a transcriptionally independent 
manner. In irradiated mouse thymocytes, p53 itself translocates to mitochondria, binds to the 
anti-apoptotic Bcl-XL and Bcl-2 proteins leading to the release of cyt c into the cytoplasm 
[52]. Thus, the balance between the levels of pro-apoptotic Bcl-2 proteins and anti-apoptotic 
Bcl-2 proteins plays a critical role in determining the fate of the cell, the release of cyt c from 
the mitochondria into the cytoplasm and the subsequent activation of procaspase 9 leading to 
apoptosis. 
1.2.3.3 Execution pathway of apoptosis 
Both, extrinsic and intrinsic pathways converge at the execution pathway to follow the final 
events of apoptosis. Caspase-3/6/7 function as primary effector caspases in the execution 
pathway [53]. Activation of the effector caspases leads to the cleaving of PARP, NuMA, 
cytokeratins and other proteins that are responsible for the characteristic morphological and 
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biochemical changes observed in apoptotic cells [54]. Activation of caspase-3 through the 
initiator caspases – 8/9/10 specifically activates CAD, which otherwise would be inhibited by 
complexing with its inhibitor, ICAD. Activation of CAD results in the degradation of 
chromosomal DNA [53]. Caspase-3 cleaves gelsolin, an actin polymerization protein and 
thus leading to the formation of apoptotic bodies through cytoskeletal disintegration. The 
process of apoptosis culminates by the massive externalization of phosphatidylserine present 
in the cell membrane’s lipid bilayer. The apoptotic cells with exposed phosphatidylserine 
molecules are recognized by phagocytic cells to be cleared off by endophagocytosis. 
Thus, p53 dependent apoptosis is mediated through the induction of its downstream pro-
apoptotic target genes Bax, Puma, Noxa and Fas. However, recent studies has shown that 
apoptosis and cell cycle arrest are dispensable functions for p53 mediated tumor suppression 
[55], and the expression of Puma, Noxa and p21 are unessential for p53 mediated tumor 
suppression [56].  This suggests other p53 transcriptional targets and mechanisms such as, 
metabolism to be involved in p53 mediated tumor suppression. 
1.2.4 Post-transcriptional gene regulation 
The most well defined and commonly referred mechanism of gene regulation by p53 is 
through its ability to bind to DNA and activate transcription. p53 can also indirectly regulate 
gene expression at the post-transcriptional level through the induction of specific target genes 
that regulate the stability of target mRNA. Zink finger domain containing Wig-1 is one such 
p53 target [57, 58] that can regulate the stability of certain mRNAs by binding to site specific 
AU-rich region on the 3’UTR [59]. Wig-1 has been shown to regulate p53 mRNA by a 
positive feedback loop mechanism. Binding of Wig-1 to the AU-rich 3’UTR of p53 mRNA 
stabilizes it by preventing its deadenylation.  This Wig-1 mediated stabilization of p53 
mRNA is reflected on the increased p53 protein levels and its response to DNA damage. 
Other 3’UTR binding proteins like, human antigen R (HuR) [60] and ribosomal protein L26 
(RPL26) [61] have also been shown to stabiles p53 mRNA and enhance its translation. 
mRNA stability is also regulated by short non-protein coding micro RNAs (miRNAs) which 
are incorporated into a RNA-induced silencing complex (RISC). As the name suggests, the 
miRNAs negatively regulate gene expression by forming a complex with the target mRNA 
and subjecting it to mRNA degradation.  p53 is known to induce the miR-34 family 
consisting of miR-34a, b and c [62-65]. The miR-34 family was shown to repress tumor 
growth and metastasis through inhibition of genes contributing to cancer progression, EMT, 
metastasis and stemness of cancer cells (examples). In the immunological context, p53 
dependent expression of miR-34a is essential for the repression of IL-6 receptor, thus 
inhibiting the STAT3 signaling [66]. 
1.2.5 p53 in immune system 
p53 knockout mice have been a very useful animal model to study the contribution of p53 to 
various biological processes and the damage done to the system in its absence. Such mice are 
prone to develop T cell lymphomas in spite of an apparent normal T lymphocyte 
  7 
development and immune response [67, 68], underlining p53’s role in regulating T cell 
proliferation. Also, CTLs from p53 mutant mice expanded more efficiently than from p53 
wild type mice [69], again indicating a role for p53 in regulating T cell proliferation. Similar 
observations were made in p53 silenced humanized mouse model, normal T cell development 
and a normal immune response to antigen stimulation. However, upon prolonged antigen 
stimulation, p53 silenced T cells showed a significant growth advantage over T cells 
expressing p53 [70]. 
Despite studies in p53 knockout mice that showed that p53 loss has no significant influence 
on the T cell development and function, recent studies suggest p53 regulates genes involved 
in the immune response. p53 has been shown to regulate IL6 expression [66] and polarization 
of macrophages to M2 [71]. 
1.3 T lymphocytes 
Bone marrow is the site of generation of the common lymphocyte progenitor cells. These 
cells migrate to the thymus where they rearrange their TCR genes [72], mature and undergo 
differentiation to give rise to the two major subtypes of T cell, CD3+ CD4+ and CD3+ 
CD8+. T cells are among the most versatile cell in the body. The complex T cell receptor 
(TCR) they express on the cell surface recognizes its cognate ligand, an antigen peptide 
bound to major histocompatibility complex (MHC) class I or class II [73]. Those T cells that 
recognize MHC bound self-antigens are self-reactive and are eliminated by apoptosis, a 
process called negative selection. T cells whose TCR fail to bind peptide bound MHC also 
undergo apoptosis, a process called death by neglect [74]. T cells that survive differentiate 
into either CD4+ or CD8+ cells. 
T cells have diverse but distinct functions based on their state of differentiation in the 
peripheral immune system. 
CD4+ T cells are highly divergent in their differentiation, function and cytokine profile [75]. 
CD4+ T cells help B cell maturation, activation and antibody production. They also activate 
cytotoxic T cells or they suppress the immune reaction. The following CD4+ T cell subsets 
have been identified and characterized. 
T helper type 1 (Th1) cells: IL12 and INFγ secreted by dendritic and NK cells initiate the 
differentiation of Th1 cells [76]. INFγ produced by Th1 cells inhibit the development of Th2 
and Th17 cells [77]. Th1 cells are important for host defense against viral and intracellular 
bacterial pathogens. 
T helper type 2 (Th2) cells: IL4 and IL2 are critical for Th2 cell differentiation [78]. IL6 
produced by APCs also promotes Th2, but inhibits Th1 lineage differentiation [79]. Th2 cells 
are important for host defense against extracellular pathogens and are also important for 
allergic responses. 
 8 
T helper type 9 (Th9) cells: Subset of Th2 cells that differentiate to IL9 producing Th9 cells 
induced by IL4 and TGFβ [80]. Abnormal increase in Th9 cells is associated with allergic 
inflammation [81] and autoimmune encephalitis [82]. 
T helper type 17 (Th17) cells: IL6, IL21, IL23 and TGFβ are essential for the differentiation 
of Th17 cells [83]. IL17A and IL17F are the major cytokines secreted by Th17 cells [84]. 
This T cell subtype has been implicated in pathological and protective role during 
inflammation. 
T helper type 22 (Th22) cells: This subset of CD4+ T cells are recruited to skin where they 
defend against microbial pathogens, but are also associated with inflammatory skin disorders. 
These cells secrete high levels of IL22 and INFα [85]. 
Follicular helper T (Tfh) cells: These cells are involved in the regulation and development of 
antigen-specific B cell immunity. The surface markers for Tfh cell identification are CXCR5 
along with ICOS, PD-1. They also express high levels of SAP. Tfh cells are localized in the 
follicles of lymph nodes and express BCL6 [86]. 
Regulatory T (Treg) cells: Treg cells are characterized as CD4+ CD25+ cells that express 
FoxP3. They comprise 5-10% of the total CD4+ cells and negatively regulate innate and 
adaptive immune responses [87]. These cells are responsible for maintaining immune 
homeostasis via inhibition of differentiation and activity of pro-inflammatory T helper cells. 
FoxP3 expression is the most commonly used marker for Treg cells in mice and humans. A 
specific subtype of regulatory cells has been described in the germinal center as well, Tfr, 
where Foxp3 is expressed in cells that carry the markers of Tfh cells: CD4+ CXCR5hi 
PD1hi.  Human Treg cells are further differentiated by low expression levels of CD127 [88]. 
Natural killer T (NKT) cells: These cells mature in the thymus but also express NK lineage 
receptors. They are immunomodulatory CD1d restricted T lymphocytes that recognize lipid 
antigens [89]. 
CD8+ cytotoxic T lymphocytes (CTLs): These T cells express an alpha beta T cell receptor 
(TCR) and execute the direct killing of virus infected, damaged, and tumor cells. CTLs most 
commonly produce IFNγ following TCR stimulated activation.  The cytotoxic function of 
CTLs is accomplished by establishing physical contact with the target cells, followed by 
Perforin mediated pore formation and the release of the serine protease granzyme B into the 
target cells. In the target cell granzyme B activates procaspase 3 and Bid to trigger the 
intrinsic apoptotic pathway. The population of activated CTLs predominantly consists of 
short-lived effector cells, which die rapidly after the infection has been cleared, but a small 
group of antigen specific effector cells make up the memory cell population [90]. 
T cell survival is influenced by the signals the cell receives through the TCR complex, CD4 
or CD8 co-receptors and co-stimulatory molecules (including CD28), adhesion molecules 
and cytokines (such as interleukin 2 (IL2), IL13 and IL15) [91]. Proliferation and resistance 
towards T cell death can be regulated by several cytokines like, IL2, IL4, IL7, IL15 and IL21 
  9 
[92]. Among the ILs, IL7 is an important pro-survival signal for naïve T cells. IL7/IL7Ra 
interactions result in activation of STAT5 and delayed but sustained AKT activation, these 
signaling pathways are critical for IL7-mediated uptake of glucose [93]. 
1.3.1 Regulation of lymphocyte population 
The immune system plays a critical role in safeguarding the host against pathogens. Cells of 
the immune system function with a great degree of specificity directed towards a particular 
antigen. In response to an antigen, naïve immune cells are sensitized to bring about changes 
in morphology and cellular functions to generate effector cells. The effector cells by 
themselves or with aid from other cells counteract the pathogens or the pathogen infected 
cell/s. The engagement of specific antigen receptors on cell surface triggers the process of 
activation. Activation of immune cells is followed by their increased proliferation and/or 
motility and execution of their effector functions. Following a successful immune response, 
the immune system starts to shutdown, characterized by the dramatic decrease in the number 
of activated cells. This shutdown of the immune system is facilitated by the cessation of 
proliferation and apoptosis of activated cells. This process also promotes the restoration of 
resting state, thus establishing homeostasis. 
The shutdown of T cell response is brought about by apoptosis of activated T cells, allowing 
the decline in its number (contraction phase). Activation induced cell death (AICD) and 
activated T cell autonomous death (ACAD) are two concepts that explain homeostatic 
regulation of T cell immune responses. 
1.3.1.1 Activation induced cell death (AICD) 
The most well characterized mechanism of apoptosis in activated T cells is through the 
interaction of FasL (APO-1L) and its corresponding Fas receptor (CD95) [42]. Mouse models 
with defective FasL/Fas genes have been shown to have defective apoptotic mechanism to 
regulate T cell population leading to lymphoproliferation and autoimmunity [94, 95]. 
Interaction of the FasL/Fas induces the formation of DISC, composed of trimearised Fas, 
FADD and two procaspases-8 and 10. Formation of DISC helps the activation of these 
procaspase that will initiate the progress through the apoptotic pathway. In this sequence of 
events the initiator caspases-8 and 10 are critical to transmit the apoptotic signal downstream 
to the effector caspases [96]. 
The apoptotic signal initiated through the activation of Fas receptor and transduced through 
the formation of DISC also relies on the destabilization of mitochondria to amplify the 
apoptotic signals downstream. The cross talk between the receptor dependent apoptosis and 
the mitochondria dependent intrinsic apoptotic pathway is mediated through the caspase-8 
cleavage of Bcl-2 family member-Bid, giving rise to truncated Bid (tBid) [97]. The 
mitochondrial membrane is destabilized by tBid, releasing cytochrome c into the cytosol. 
This facilitates the formation of apoptosome and activation of caspase-9, which in turn 
activates the effector caspases, culminating in apoptosis [98]. 
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1.3.1.2 Inhibition of AICD 
Fas expression is upregulated with the activation of T cells indicating that T cells are 
programing themselves for apoptosis very early during an immune response. However, 
during activation and expansion phase of the immune response T cells evade apoptosis 
induced through Fas by regulating the level of activated caspases8/10. This regulation of 
caspases during early stage of activation is brought about by the competitive binding of 
cellular FLICE-inhibitory protein (cFLIP) to FADD molecules [99]. The ratio between 
procaspases and cFLIP available to bind to FADD determines the initiation of apoptosis. The 
binding of cFLIP to FADD has been implicated in the negative regulation of AICD [100]. 
Several isoforms of cFLIP have been reported of which cFLIP long and short (cFLIPL and 
cFLIPS) have been associated with the inhibition of AICD [101]. The expression of c-FLIPS 
is strongly upregulated upon initial T cell activation. Co-stimulation of T cells via CD28 
elevates cFLIPS expression providing resistance to apoptosis during the early stages of T cell 
activation, thus facilitating clonal expansion [102]. With the decline of cFLIPS expression, 
Fas dependent AICD is initiated as procaspase-8/10 molecules are now able to bind to FADD 
enabling the formation of DISC. The mitochondrial apoptotic pathway is also inhibited 
during the initial T cell activation and expansion through the action of cFLIPS and the anti-
apoptotic Bcl-XL. The mitochondria dependent apoptotic machinery is inhibited through the 
binding of Bcl-XL to the pro-apoptotic Bcl-2 proteins.  Thus through the expression of 
cFLIPS and Bcl-XL during the initial phase of activation and expansion, T cells resist Fas 
mediated apoptosis. 
 
Figure: Activation induced cell death pathway [109]. 
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1.3.1.3 Activation cell autonomous death (ACAD) 
In absence of the appropriate survival signals (i.e. cytokine depravation), activated T cells are 
subjected to ACAD, that is apoptosis independent of the cell death receptor pathway [103]. 
Under such circumstances expression of pro-apoptotic Bcl-2 family proteins BIM and PUMA 
increases and they induce ACAD through the intrinsic apoptotic pathway that destabilizes the 
mitochondrial integrity [104, 105]. It has been reported that during the immune contraction 
phase BIM expression levels are elevated. Binding of BIM to pro-survival Bcl-2 will allow 
the release of cyt c through the pro-apoptotic function of Bak and Bax. Understanding precise 
mechanism of ACAD in vivo is of great interest. It is postulated to play a significant role in 
regulating T lymphocyte homeostasis during low antigen load, while AICD regulates T cell 
deletion during high antigen load. 
1.3.1.4 Cytokine mediated regulation of T cell survival 
T cell survival is also influenced through a number of cytokines. IL2 is an essential cytokine 
for activated T cells that helps proliferation, thus the establishment of a protective immune 
response [106]. Naïve T cells that are resistant to AICD, produce IL2 following activation 
and also express its high affinity IL2Rα (CD25) [107]. IL2, through the PI3K pathway, can 
induce the expression of antiapoptotic Bcl-2 proteins, protecting the cells from apoptosis. 
However, studies in mouse models deficient in IL2 or CD25 show impaired AICD, 
suggesting the requirement of IL2 for effective AICD [108]. The increase in FasL and 
decrease in c-FLIP expression at the end of the expansion phase has been postulated to be IL2 
dependent. 
IL15 is another cytokine that shares the same IL2α receptor and it also stimulates T cell 
proliferation. However, IL15 can inhibit IL2 dependent sensitization for AICD [109]. 
IL7 is crucial for T cell development, deficiency of which is associated with the development 
of severe combined immunodeficiency (SCID). IL7rα deficiency has been associated with 
low expression of pro-survival Bcl-2 proteins, leading to impaired T cell survival [110]. 
1.4 Epstein-Barr virus (EBV) 
Human herpesvirus 4, Epstein-Barr virus (EBV) is a gammaherpesvirus, leading to one of the 
most common viral infections in humans, with around 90-95% of adult population being 
infected. EBV is a double stranded DNA virus. It was first identified while studying Burkitt 
lymphoma (BL), a B cell lymphoma [111, 112]. Following the discovery of EBV, its ability 
to transform B cells in vitro was established [112, 113]. This in vitro system of 
transformation was exploited to study the mechanisms of EBV induced B cell transformation 
and the immune response mounted against it. Based on the in vitro findings, EBV was 
considered to be the driving force behind the mechanism in the development of BL. 
However, the discovery of EBV negative BL which shared similar cytogenetics and 
pathology with EBV positive BL, suggested that EBV was not the primary cause of BL, but 
likely contributes to its pathogenesis. 
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EBV preferentially infects B lymphocytes and epithelial cells. The viral gp350 and gp42 
proteins bind to CD21 and HLA class II molecules on B cells and facilitates entry of EBV 
into the cells [114, 115]. Epithelial cells do not express CD21, here the fusion occurs through 
the viral BMRF-2 and gH/gL envelop proteins binding to β1 and ανβ6/8 integrins 
respectively [116]. Primary EBV infection most often occurs during the early childhood and 
is asymptomatic. If the primary infection is delayed, about half of the infected individuals 
develop a self-limiting lymphoproliferative disease called infectious mononucleosis (IM) or 
more popularly known as the kissing disease. IM is typically characterized by lymphocytosis 
of CD8+ T lymphocytes. Following the recovery from IM, EBV continues to persist in the 
infected host for the rest of the individual’s life as an asymptomatic infection [117]. 
1.4.1 Type III latency 
In vitro infection of B cells with EBV establishes a latent infection giving rise to transformed 
lymphoblastoid cell lines (LCLs). Six EBV nuclear antigens (EBNA1-6) and three membrane 
associated proteins (LMP1, LMP2a and LMP2b) were characterized in LCLs. In these cells, 
the virus uses one of its two promoters (Wp or Cp) to generate a single giant mRNA. The 
mRNAs for the six EBNAs are spliced from this giant mRNA. EBV gene expression of this 
pattern is called the growth program – type III latency. The virus also encodes noncoding 
RNAs, EBER1&2, BanHI-A rightward transcripts (BARTs) and miroRNAs. The Bcl-2 
homologs, BALF1 and BHRF1 are transiently expressed during the early stage of primary 
infection [118]. The virus encodes 23 well characterized miRNAs that are expressed in two 
clusters: the BART cluster that encodes 20 miRNAs, highly upregulated in latently infected 
epithelial cells and low levels in B cells. BHRF1 is the other cluster encoding 3 miRNAs, 
upregulated in type III but not detectable in type I/II latent B or epithelial cells. The 
expression of viral proteins and miRNAs interacts and influences various host proteins, 
miRNAs and thus cell signaling mechanisms. Of all the viral proteins expressed, EBNA-2, 3, 
5, 6, LMP-1, BALF1 and BHRF1 are essential for in vitro B cell transformation. 
The EBV genome is linear in the virion, but following infection of B cells it is circularized 
and maintained as an extra chromosomal circular structure called, episome. EBNA-1 is 
critical for maintaining the EBV episome. It binds to the origin of plasmid replication (oriP) 
and anchors it to the host chromosomes during mitosis, thus duplicating and partitioning the 
viral genome during cell division [119]. In addition to its role in maintaining the viral 
episome, EBNA-1 has also been shown to play an anti-apoptotic role in EBV carrying 
malignant cells [120]. 
EBNA-2 is the first viral protein expressed following infection [121]. It contributes to the 
establishment and maintenance of type III latency through the activation of LMP-1, -2 and 
Cp promoters. It trans-activates the through hijacking the Jκ recombination signal binding 
protein (RBP-jκ), the major transcriptional factor involved in Notch pathway [122-124]. 
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EBNA-5 is among the first viral proteins along with EBNA-2 to be expressed following B 
cell infection [125]. Forming a trimolecular MDM2-p53-EBNA5 complex, the 
transactivation function of p53 is abrogated [126]. 
LMP-1 is a glycoprotein that acts as a constitutively active CD40. It activates the NF-κB, 
MAP kinase, phosphatidylinositol 3-kinase (PI3K) and ERK-MAPK signaling pathways 
[127, 128]. With the engagement of multiple signaling pathways, LMP-1 expression induces 
expression of anti-apoptotic proteins (cFLIP, cIAP1 & 2, Mcl-1) that contributes to the 
survival of EBV infected B cells [129, 130]. Genes involved in cellular adhesion (ICAM-1, 
SLAM, CD40, CD48, LFA-1 & 3) and also those that are associated with metastasis (VEGF, 
Cox-2, MMP-1 & 9) are induced with the expression of LMP-1 [131]. On the contrary, E-
cadherin and BCL6 are repressed by LMP-1 [132-134]. Thus LMP-1 is a major transforming 
protein of EBV required for efficient B cell immortalization. Studies on transgenic mice have 
confirmed that LMP-1 mimics an active CD40 receptor and aids B cell activation and 
differentiation [135]. B cells of mice lacking CD40 receptor but expressing LMP-1 
demonstrated ability to proliferate, enhanced expression of activation antigens and underwent 
extrafollicular B cell differentiation. However, LMP-1 blocked germinal center (GC) 
formation even in the presence of CD40. This inhibition of CG formation is through LMP-1 
mediated repression of BCL6 [127]. Expression of LMP-1 in BL cells inhibited proliferation 
plausibly through the suppression of BCL6. 
1.4.2 Type IIa latency 
In this EBV gene expression pattern, only one nuclear antigen EBNA-1 along with LMP-1 
and -2 are expressed. This pattern of EBV gene expression was first observed in 
nasopharyngeal carcinoma (NCP) [136, 137]. Other malignancies associated with type IIa 
latency are, the classical Hodgkin lymphoma, EBV positive T and NK cell lymphomas. 
Unlike in type III latency where the transcription of EBNA mRNAs originate from Cp or 
Wp, in type II latency a different promoter, BamHI Q-region (Qp) drives the exclusive 
transcription of EBNA-1 only [138-140]. Also, the expression of LMP-1 and -2 are 
differently regulated due to the lack of EBNA-2 expression. 
1.4.3 Type IIb latency 
This special latency program was identified in B-chronic lymphocytic leukemia (B-CLL) 
cells infected in vitro with EBV [141]. It expresses all six nuclear proteins, EBNA1-6, but 
lack LMP-1 expression [117]. The in vitro infection of B-CLLs with EBV does not yield 
LCL, consistent with the requirement of the expression of LMP-1 for B cell immortalization 
[142]. EBV is not involved in the pathogenesis of B-CLL in vivo and in vitro occurrence of 
EBV positive B-CLL clones are also extremely rare. The lack of LMP-1 despite EBNA-2 
expression in the type IIb latency is intriguing, but there is still no explanation for it. This 
type of latency program has been reported not only in in vitro infected B-CLL cells, but it has 
been detected by immunohistochemistry in lymphoid tissues of PTLD, IM patients and EBV 
infected humanized mouse models as well [117]. 
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1.4.4 Type I/0 latency 
This is the ‘EBNA-1 only’ expression patter of EBV. Similar to the type II latency ENBA-1 
transcription is driven by the Qp [143]. Endemic BLs are a classic example of type I latency 
program. EBNA-1 is essential for the replication of the viral eposome and its distribution to 
daughter cells during mitotic division [144, 145]. EBV carrying B cells that are not subjected 
to mitotic division express the non-translated viral RNAs, the EBERs. This viral latency 
program where only the EBERs are expressed is classified as type 0 latency. 
1.4.5 T lymphocyte response to EBV infection 
In most cases, EBV infection is not life threatening as it is effectively controlled by the host 
immune response [146]. In response to EBV infection both the humoral and cellular immune 
systems are activated. Antibodies generated against the viral antigens are exploited for the 
diagnoses of the infection. 
The HLA class I restricted CD8+ T cell response to EBV infection during IM is the most 
profound and important immune compartment regulating the infection [147]. Early studies of 
CD8+ response to EBV employed the in vitro system of challenging PBLs to autologous 
LCL (latency III) in order to generate CD8+ T cell lines specific for EBV antigens. From 
these studies, the identified epitopes were most often derived from EBNA-3, -4 or -6 and less 
often from other latent proteins, but least likely from EBNA-1 [148, 149]. A glycine-alanine 
repeat domain in EBNA-1 was identified to protect it from proteasomal degradation for MHC 
class 1 processing [150]. However, several class II restricted EBNA-1 peptides have been 
identified in vivo studies on IM cases showing that half of the CD8+ response is highly 
focused against proteins of the early lytic cycle – BZLF1, BRLF1, BMLF1 and BARF1 [151-
154]. It was also observed that in most individuals CD8+ response was generated against 
more than one EBV antigen. 
Very early studies of HLA class II CD4+ cell response to EBV during IM reported no or very 
little increase in their numbers [155]. However, with the development of HLA class II 
tetramer techniques it has been possible to identify subtle bursts of EBV specific CD4+ T cell 
response [156], although not matching the CD8+ T cell response neither in size nor in 
activity. Studies have shown that both lytic and latent proteins released from infected B cells 
were cross-presented by neighboring antigen presenting cells to be recognized by CD4+ T 
cells. However, unlike the CD8+ T cell responses, the CD4+ T cell response leaned more 
towards latent than lytic antigens [157]. EBNA-1 specific CD4+ T cells were found more 
frequently in virus carrying healthy individuals but barely detectable in acute IM [152, 158], 
reiterating EBNA-1’s poor ability to be processed and presented by antigen presenting cells. 
1.4.6 EBV’s way to memory B cells 
It is well established that once infected, EBV is harbored in memory B cells for the rest of the 
individual’s life. The frequency of EBV infected B cells in the blood of IM patients range 
from 1in 2 to 1 in 10
2
 memory B cells [159]. However, in healthy carriers the frequency of 
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EBV carrying B cells is far much lower, ranging from 1- 50 in 10
6
 B cells [160]. Type III 
latency, similar to the gene expression pattern LCL is found during IM, but such cells owing 
to their high immunogenicity are efficiently eliminated by the cellular immune responses.   
Studies of on EBV positive tonsilar B cell subpopulations reveled that, type III latency 
pattern was restricted to the naïve B cell population, while type II latency was restricted to B 
cells in the GC [161]. EBV carrying memory B cells isolated form blood express type I/0 
latent viral gene expression with no detectable LMP-1 mRNA, but very low LMP-2 mRNA. 
Thorley Lawson postulated a theory on how EBV gains access to the memory B cell pool 
[162]. According to this theory – the majority of the EBV infected naïve B cells expressing 
the type III pattern are successful eliminated, while those that escape immunesurveillance 
enter GCs and differentiate into GC B cells. These EBV carrying GC B cells express the type 
IIa latency-EBNA-2 and LMPs. As LMP-1 and LMP-2 mimics CD40 and BCR signaling 
pathways respectively, it is postulated that the signals essential for survival and 
differentiation of EBV carrying GC B cells (type IIa latency) are provided by these proteins. 
The model further postulates that the number of EBV encoded proteins will be further 
reduced in EBV harboring B cells upon leaving the GC environment. Once cells are out of 
the CG environment, the EBV infected resting memory B cells will express only the EBERs 
(type I latency). EBNA-1 expression is induced upon the stimulation of EBV positive 
memory B cells to enter cell cycle. Through the induction of EBNA-1, the viral episome is 
replicated and carried by the daughter cells. When EBV carrying memory B cells 
differentiate to plasma cells, EBV’s lytic replication is initiated to produce new virus 
progeny. 
 
 
 
Figure: EBV infection and latencies [253]. 
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1.4.7 The X linked lymphoproliferative disease (XLP) 
XLP is a rare immunodeficiency which is the result of mutations or the deletion of the 
SH2D1A/SAP (SLAM associated protein) gene [254-256]. SAP is expressed in T and NK 
cells, it binds to and modulates signals initiated through SLAM family of surface receptors. 
Individuals suffering from the XLP disease are selectively susceptible to EBV infection but 
not to other herpes virus infection. Primary EBV infection in XPL individuals results in 
uncontrolled T and B cell proliferation. 50% of XLP patients die as a consequence of primary 
EBV infection - fatal IM, the major manifestation of XLP which is caused by overwhelming 
T cell activation accompanied by impaired AICD and loss of function. The unchecked 
proliferation of T cells (caused by the loss of SAP’s pro-apoptotic function) is associated with 
extensive necrosis in the liver, bone marrow and other organs, thus resulting in fatality. CD8+ 
T cell response to EBV transformed B cells is defective in XLP patients [257, 258]. SAP 
deficient CD8+
 
T cells exhibit impaired cytotoxicity to antigens presented by B cells. 
However, the cytotoxicity exhibited by SAP deficient CD8+ T cells was similar to CD8+ T 
cells expressing functional SAP, when the same antigens were presented by other antigen 
presenting cells. This impaired function of SAP deficient CD8+ T cell fails to eliminate the 
EBV infected B cells [259]. Deficient SAP in Tfh cells affects the impending differentiation, 
affinity maturation and class switch recombination of B cells in the GC, leading to 
dysgammaglobulinemia seen in XLP patients [260]. The high incidence of malignant 
lymphomas (40%) manifested in XLP patients is also likely the consequence of deficient pro-
apoptotic function of SAP [241, 242]. 
1.5 Multiple myeloma (MM) 
MM originates from an asymptomatic premalignant proliferation of monoclonal plasma cells. 
Multistep genetic aberrations accompanied by changes in the microenvironment lead to the 
transformation into a malignant neoplasm. Multiple myeloma is a heterogeneous disease 
understood to evolve from a monoclonal gammopathy of undetermined clinical significance 
(MGUS) [163]. Unlike CML, a single driver mutation is not responsible for the manifestation 
of the disease, it exhibits a number of genetic abnormalities. However, the primary early 
chromosomal translocation in MM is the immunoglobulin switch region on chromosome 14 
(q32.33) juxtaposed to proto-oncogene MAF (t[14.16][q32.33;23]) and MMSET on 
chromosome 4p16.3 [164, 165]. The secondary, late-onset translocations and gene mutations 
that are implicated in the pathogeneses of the disease progression include complex karyotypic 
abnormalities in Myc, activation of N-Ras, K-Ras, mutations in FgFr3, p53 and the 
inactivation of CDKN2A and CDKN2C [166, 167]. 
Genetic abnormalities and chromosomal alternations adversely influence the expression of 
adhesion molecules and response to growth stimuli in the microenvironment. MM cells 
greatly rely on cellular and non-cellular components of the tumor microenvironment like, 
bone marrow stromal cells, endothelial cells, IL6, insulin like growth factors and vascular 
endothelial growth factors for their survival and growth [168]. Among these, IL6 is known to 
play an important role through the activation of STAT2/STAT3 pathway leading to increased 
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levels of anti-apoptotic Bcl-Xl and Mcl1, thus promoting survival and resistance to drug 
induced apoptosis of MM cells [169, 170]. 
Proteasomal inhibitors and immunomodulatory drugs can target the disruption of various 
signaling pathways that support proliferation, cellular growth and the survival of MM cells 
[171, 172]. Proteasomal inhibition induces multiple apoptotic pathways that include the 
induction of endoplasmic reticulum stress response [173, 174]. Proteasomal inhibition also 
inhibits NF-κB signaling, there by downregulating cell adhesion molecules, angiogenesis 
factors and cytokine signaling in the microenvironment.  Immunomodulation shows promise 
in delaying the progression from asymptomatic (smoldering) to symptomatic (active) MM 
[172]. 
1.6 Chronic myeloid leukemia (CML) 
CML is characterized by the reciprocal translocation involving the long arms of chromosome 
9 and 22, t(9;22), the Philadelphia chromosome [175, 176]. This translocation, juxtaposition 
of the 3’ sequence from ABL proto-oncogene on chromosome 9, with the 5’ sequence from 
BCR (break point cluster region) gene on chromosome 22, results in the fusion oncogene, 
BCR-ABL. CML is characterized by the over production of hematopoietic stem cells 
carrying the BCR-ABL translocation in the peripheral blood in the chronic phase (CP). With 
the progression of the disease, the patient enters an acute phase (AP) followed by the blast 
phase (BP), during which the differentiation of hematopoietic cells is arrested with the 
accumulation of immature blasts in the bone marrow and peripheral blood [177]. 
The ABL gene encodes for a non-receptor tyrosine kinase carrying SRC homology domains 
(SH1-SH3) at the amino terminal. The SH1 domain is responsible of the kinase activity while 
the SH2 and SH3 domains facilitates protein-protein interactions [178]. The ABL protein is 
nuclear localized with a nuclear localizing signal, DNA binding and actin binding motifs at 
the carboxylic terminal [179]. With the BCR-ABL chromosomal translocation in CML cells, 
the resulting fusion protein, a deregulated thyrosine kinase is localized in the cytoplasm 
allowing access to many cytoplasmic substrates. As a consequence of the fusion protein, a 
number of signaling pathways that sustain cellular proliferation are activated (RAS, MAPK, 
JAK-STAT, PI3K, Myc). STAT5 plays an important role in many biological processes that 
includes lymphocyte development and its function [180]. The deregulated kinase activity also 
inhibits the apoptotic pathways induced by DNA damage or by the withdrawal of growth 
factors [181]. Thus, CML patients have a clonal expansion of hematopoietic cells that express 
the BCR-ABL fusion protein, thus making the tyrosine kinase an obvious therapeutic target 
for controlling the disease. 
The very first therapy was hydroxyurea or busulfan which had little or negligible effect on the 
disease outcome. Later studies demonstrated that INFα had a positive effect in the 
management of CML, proving to be promising when compared to hydroxyurea and bisulfan 
[182, 183]. With the better understanding of the mechanism of the constitutive kinase activity 
of BCR-ABL in the pathogenesis of CML, molecular targeting of the kinase by chemical 
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inhibitors was initiated. Imatinib mesylate (IM), a tyrosine kinase inhibitor has been the most 
effective treatment so far of Ph positive CML [184]. Despite the positive clinical outcome of 
IM treatment, there are a considerable number of CML patients developing resistance to the 
drug, leading to the development of next generation tyrosine kinase inhibitors such as 
nilotinib (NI) and dasatinib.  The resistance to IM and NI are poorly understood. They have 
been attributed to point mutations and other BRC-ABL independent mechanisms like the role 
of the microenvironment.  A couple of studies indicate that INFγ levels are elevated in 
patients treated with IM [185]. Also, treatment with IM does not eradicate CML cells 
entirely, CML stem cells remaining unaffected [186]. These stem cells, despite their small 
number are capable of reinitiating leukemia upon discontinuation of tyrosine kinase inhibitor 
(IM) treatment. 
1.7 Interferon gamma (INFγ) 
The discovery of interferons (INF) was initially associated with biological activity during 
viral infections [187]. Subsequent studies demonstrated its diverse effects on cellular 
functions including antimicrobial responses, apoptosis and control of cell cycle [188-191]. 
INFs are secreted soluble protein molecules classified based on their receptor binding 
specificity and sequence homology. Type I INFs (INFα, β, ω and τ) share structural similarity 
and bind to a common heterodimeric receptor - INFα/β receptor.  Most cell types secrete 
traces of type-I INFs, however INFα and ω are predominantly secreted by hematopoietic cells 
and INFβ by fibroblasts and activated macrophages [192, 193]. INFγ is the only type II IFN 
that is secreted predominantly by activated T and NK cells, but less often by APCs, B and 
NKT cells [194-196]. Cytokines IL12 and IL18 secreted by APCs promote INFγ production 
by stimulating T, NK cells and macrophages during immune response to infections. 
Signaling of INFγ from the cell surface is transduced through the Janus family of kinase 
(JAKs: JAK1-3 and Tyk2) - signal transducer and activator of transcription (STATs1-6, 
including STAT5a and STAT5b) to the nucleus of the cell. This signal transduction 
machinery involves sequential receptor recruitment and the activation of JAKs and the 
STATs. The heterodimerisation of two molecules each of INFGR1 and 2 constitute the INFγ 
receptor [197]. The binding of biologically active INFγ dimer to IFNGR1 triggers the 
autophosphorylation and activation of JAK2 and the subsequent JAK1 phosphorylation by 
JAK2 [198]. An activated JAK1 molecule phosphorylates the two IFNGR1 chains at tyrosine 
440, creating docking sites for the SH2 domain containing STAT1 molecules [199]. The 
recruitment of STAT1 molecules to the INFGR1 results in the JAK2 mediated canonical 
phosphorylation of STAT1 at the C terminal tyrosine 701 [200]. The four critical 
phosphorylation steps until this stage (in sequence, JAK2-JAK1-INFGR1-STAT1) occur 
within as short as one minute of the cells exposed to INFγ. Phosphorylation of STAT1 results 
in its homodimerization and dissociation form IFNGR1 [199]. Dissociated STAT1 dimers 
enter the nucleus to regulate transcription of specific target genes via binding to specific 
response elements on DNA [201, 202]. The transcription initiation of INFγ induced genes 
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occurs within 30 minutes of INFγ stimulation of cells, transcriptional factor like IRF-1 being 
among the first to be transcribed. 
1.7.1 Regulation of STAT activity 
The STAT proteins consist of seven conserved domains. The amino terminal is implicated in 
the homotypic dimerization of inactive STAT molecules. This domain is known to facilitate 
STAT binding to tandem γIFN activation site (GAS) elements on the DNA and it also plays a 
role in the cytoplasmic-nuclear shuttle of STAT molecules [203, 204]. 
The characteristic feature of STAT signaling is its rapid turnover, with a sharp initiation of 
signaling and subsequent decay. Activated STAT molecules rapidly accumulate in the 
nucleus of the cell, but following the signal decay the STAT molecules are exported back to 
the cytoplasm to carry out the next wave of signaling. The signal decay is strongly associated 
with downregulation of cytokine receptors, JAK and also the STAT’s transcriptional 
function. The activation of STAT molecules holds the key for the cytokine elicited signal 
transduction to reach the nucleus and transactivate specific target genes. Thus mechanisms 
that decay STAT signaling are critical in the rapid turnover of STAT signaling. Three 
mechanisms that are involved in the decay of STAT signaling are well characterized: 
Dephosphorylation: Phosphatases play a crucial role in regulating the activity of kinase based 
STAT signaling. Phosphatases like SHP-1, 2 and CD45 have been associated with the decay 
of cytokine mediated Jack-STAT signaling [205, 206]. Later studies identified the role of 
PTP1B, TC-PTP and PTP-BL in dephosphorylation of STATS [206, 207]. Among these 
phosphatases, SHP-2 and TC-PTP have been implicated in the dephosphorylation of STAT 
molecules in the nucleus, a critical step in STAT signal decay and its nuclear export [204]. 
Cytoplasmic-Nuclear shuttle: The nuclear accumulation of STAT is an indication of the 
active state of the molecule. The predominant site of localization during inactive state is the 
cytoplasm. The nuclear import and export of STAT molecules is tightly regulated by nuclear 
export sequence (NES) and nuclear localization sequence (NLS) elements [208]. 
Regulation by SOCS: STAT activation is directly antagonized by its own set of 
transcriptional target - suppressors of cytokine signaling (SOCS) proteins (SCOS1-7 and 
CIS), resulting in a feedback loop regulation. STAT molecules directly regulate the 
expression of SOCS1, SOCS3 and CIS but not SOCS2 [209], for example in mouse 
fibroblast cell line NIH-3T3, INFγ induces SOCS1 and SOCS3 expression [210, 211]. The 
STAT induced SOCS proteins negatively modulate the JAK-STAT signaling by competing 
with the STAT molecules to bind to the phosphorylated tyrosine sites on the receptor and also 
by binding to JAK molecules thorough their SH2 domain and inhibiting their activity. The 
SH2 domains on the SOCS proteins function like an adaptor and thus can facilitate the 
ubiquitination and subsequent proteosomal degradation of associated signaling proteins 
[212]. 
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1.7.2 Non-canonical modifications of STAT 
Serine phosphorylation: with the exception of STAT2 all other STATS are phosphorylated on 
the serine residues on the transcriptional activation domain (TAD) [213]. Phosphorylation 
occurs on conserved serine residues situated in PMS*P motif (Ser727 in STAT1 and 3, 
Ser721in STAT4), PS*P motif (Ser725 in STAT5a and Ser730 in STAT5b) and SS*PD 
motif (Ser756 in STAT6) [214]. STAT1 and 5 have an additional phosphorylation site, 
Ser708 and Ser779 respectively. In vitro studies have identified the following kinases 
involved in STAT modifications: MAPK (p38MAPK: STATs1,3,4; ERK: STAT3,5; JNK: 
STAT3), PKCδ (STAT1 and 3), mTOR (STAT3), NLK (STAT3) and CAMKII and IIKε 
(STAT1) [213, 215]. The phosphorylation of serine regulates the transcriptional activity of 
STATs. A mouse model with a STAT1S727A mutation has defective INFγ mediated innate 
immune response [216]. Also, T cells carrying STAT4 S721A mutation show impaired IL12 
following INFγ stimulation [217]. 
Acetylation: Reversible acetylation of lysine residues on STAT1, 3 and 6 have been reported 
to regulate their function. Acetylation of STAT1 and 3 impairs NFκB signaling, resulting in a 
STAT1 mediated pro-apoptotic and STAT3 mediated anti-apoptotic effect [217, 218]. 
Acetylation of STAT3 contributes to the regulation of its transcriptional function and to the 
stability of its homodimers [219, 220]. 
Glycosylation: O-glycosylation of Thr92 on STAT5 increases its affinity to the co-activator 
CBP, thus increasing the transcriptional function of STAT5. The Thr92 residue is conserved 
in STAT1, 3 and 6 [221]. 
1.8 BCL6 
BCL6 is a transcriptional factor characterized by an amino terminal BTB/POZ domain and 
six zinc finger DNA binding motifs at the carboxylic terminal [222]. The intermediate 
backbone constitutes of three PEST domains involved in protein stabilization and activity 
[223]. BCL6 is an oncogenic master gene regulator, which may suppress the expression of 
over 1200 genes. The target genes are repressed through direct recruitment of class I and II 
histone deacetylase complex (HDAC) or via the recruitment of other co-repressors [224, 
225]. Depending on the recruitment of a specific co-repressor, different subsets of target 
genes are repressed.  Most often transcriptional activity of BCL6 is accomplished by its 
binding to specific DNA motifs via the carboxylic terminal zinc finger domain. Interferon 
regulatory factor 4 (IRF4) and STATs have been established to compete with BCL6 for 
certain promoters of target genes. Transcriptional factors FoxO1, FoxO3a, FoxO4, STAT1, 
STAT3, and IRF8 are shown to induce BCL6 expression [226, 227]. 
The most significant role of BCL6 is in the regulation of transcriptional program preventing 
premature activation and differentiation of germinal center (GC) B cells [228, 229]. Somatic 
hypermutations (SHM) and class switch recombination (CSR) in B cells during the GC 
reaction increases immunoglobulin diversity and affinity for antigens. The execution of SHM 
and CSR involves double stranded DNA brakes, a damage which should trigger a p53 
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response [230]. However, CG B cells tolerate these dsDNA breaks, though BCL6 mediated 
suppression of p53 [231]. 
BCL6 auto regulates its transcription by binding to the 5’ promoter region and suppressing its 
own transcription. This is substantiated by the identification of mutations in the BCL6 
binding sites on the first noncoding exon of the gene that prevents BCL6 binding, thus 
impending its negative regulation and potentially contributing to lymphoma genesis [232]. 
BCL6 promoter has two regions (region A and B), each with several STAT binding motifs 
[233]. ChIP sequencing data set from various human cell types show STAT3 binding to both 
regions while STAT5 binds to only region B.  STAT5 and STAT3 have been shown to 
reciprocally regulate BCL6 expression in breast cancer cell lines, STAT3 induces while 
STAT5 repressed BCL6 expression [234]. This repression by STAT5 is dominant over 
STAT3 mediated induction. 
During B cell differentiation towards memory and plasma cells, post transcriptional 
modifications of BCL6 in the PEST domain also regulates its function. Acetylation of lysine 
residues by p300 in the PEST domain of BCL6 has been associated with impaired 
recruitment of co-repressors to target site [235]. Antigen engagement of BCR activates the 
MAPK pathway, phosphorylation of serine residues my MAPK following BCR engagement 
allows ubiquitilation and the subsequent proteasomal degradation. CD40-CD40L signaling in 
the GC B cells suppresses BCL6 transcription by the binding of NF-κB induced IRF4 to the 
promoter region of BCL6 [236]. 
The oncogenic role of BCL6 was first established in DLBCL, an outcome of the 
chromosomal translocation 3q27 [237]. Heterologous promoter juxtaposed to the 5’-end of 
BCL6 gene drives its expression. Promoters of genes that are constitutively active in B cell 
lineage such as, IgH, IgL, PAX5 and H4 often drive BCL6 expression in tumors originating 
from the GC [238]. Given the fact that BCL6 provides tolerance to dsDNA breaks in GC B 
cells, it may prove a persistent tolerance to DNA damage, thus abetting the accumulation of 
oncogenic mutations [239]. The wide spread expression of BCL6 in GC derived lymphomas 
make it a potential therapeutic target. 
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2 AIM OF THIS THESIS  
 
The following questions were addressed in the thesis, 
1. Does p53 contribute to the regulation of homeostasis in activated T cells? 
2. Are CD4+ T cells involved in the modulation of EBV gene expression? 
3. Does INFγ regulate BCL6 expression in MM and IM treated CML cells? 
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3 RESULTS AND DISCUSSION  
 
p53 contributes to the regulation of T cell homeostasis through the induction of pro-
apoptotic SAP and suppression of cMyc in activated T cells (Papers I and II) 
Results from our laboratory have previously shown that wt p53 induces SAP expression in 
Burkitt lymphoma cell lines following DNA damage [240] and led to the discovery of SAP’s 
pro-apoptotic role in T cells [241, 242] and the induction of p53 in activated T cells [241], 
suggesting its involvement in T cell homeostasis. 
As a next step we studied the kinetics of p53, SAP, cMyc, p14ARF and p21 expression in 
activated T cells. We showed that p53 and pro-apoptotic SAP expression was induced in 
activated but not in un-stimulated T cells. The kinetics of SAP expression level inversely 
corresponded to the proliferation of activated T cells. Proliferation of T cells during the initial 
activation reached a maximum and expressed lower levels of SAP, but in cells that showed 
decreased proliferation, SAP expression was elevated. The kinetics of SAP expression 
corresponded to the levels of cleaved PARP, also indicating that activated T cells expressing 
higher levels of SAP undergo apoptosis. 
The E3 ubiquitin ligase-MDM2 inhibitor, nutlin-3, facilitated selective induction of p53 [243] 
in un-stimulated T cells accompanied by SAP mRNA and protein induction, indicating that 
p53 induces SAP expression in T cells. Also, chromatin immune-precipitation assay 
confirmed the binding of p53 to SAP promoter region in activated T cells. Thus, we 
demonstrate that SAP is a transcriptional target of p53 in activated primary T cells and hence 
underlined the involvement of p53 in the regulation of T cell homeostasis through pro-
apoptotic SAP. 
cMyc was induced in activated T cells and the kinetics of its expression corresponded to the 
proliferation of activated T cells. cMyc target p14ARF accompanied the induction of p53 and 
p21 in activated T cells. Expression p14ARF and p53 remained high thought, while p21 
expression was induced only during the initial activation and declined with time.  Various 
studies have well established that p14ARF binding to MDM2 stabilizes p53 protein. This 
binding inhibits p53 degradation which otherwise is mediated through the formation of the 
MDM2-p53 complex and ubiquitination of p53 by MDM2 for proteosomal degradation. Thus 
cMyc can positively regulate p53 expression through p14ARF. At the other end, it is also 
established that p53 can suppress cMyc transcription. This motivated us to explore the 
involvement of cMyc-p53 network in regulating cell growth and survival in a model where 
cMyc and p53 pathways were unaltered. To this end, we selectively induced p53 with MDM2 
inhibitor nultin-3 and inhibited cMyc with small molecule 10058-F4 [244]. Nultin-3 
treatment of activated T cells further potentiated p53 along with its transcriptional target p21, 
but decreased cMyc expression and inhibited proliferation. Downregulation of cMyc 
accompanied low levels of p14ARF expression. Also, treatment of activated T cells with 
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nutlin-3 for a short duration (8 h) showed decreased cMyc mRNA, while p53 inducible p21 
mRNA was unregulated, indicating that elevated levels of p53 suppresses cMyc transcription. 
As activation of notch signaling during T cell immune response induces cMyc that drives the 
expansion of T cell clones, we tested the consequence of DAPT mediated Notch inhibition 
[245] on the expression of the above proteins and cell proliferation. Notch inhibition in 
activated T cells downregulated cMyc expression and decreased proliferation, 
correspondingly p14ARF and p53 expression were also downregulated. This suggested that 
p53 induced in activated T cells follow the cMyc-p14ARF pathway. cMyc was specifically 
inhibited using 10058-F4 to further confirm the involvement of cMyc-p14ARF in the 
induction of p53 in activated T cells. 10058-F4 treatment of activated T cells decreased cell 
proliferation, cMyc expression and also lowered p14ARF and p53 expression. This 
confirmed the involvement of cMyc-p14ARF in the induction of p53 in activated T cells. 
Nulin-3 induced p53 and 10058-F4 mediated cMyc inhibition induced both apoptosis and 
growth arrest in activated T cells. The cytotoxic function of activated T cells was retained 
despite the inhibitory effect of nutlin-3 and cMyc inhibitor 10058-F4 on proliferation. 
Thus, we establish the contribution of p53 in T cell homeostasis through its regulation of pro-
apoptotic SAP and proto-oncogene cMyc. 
 
EBV gene expression modulated by CD4+ secreted soluble factors (Paper III) 
EBV infects naïve IgD+ B cells, subsequently expressing nine viral encoded proteins (latency 
III), transforming cells into immunoblasts. CD8+ T cell response eliminates the majority of 
type III cells, while a fraction of infected cells migrate to the lymph node follicles where it 
undergoes changes to express only three viral proteins – EBNA1, LMP1 and LMP2 (latency 
II). Previous results from our group have studied the changes in EBV latency pattern induced 
through cytokines secreted by CD4+ T cells. IL4, IL10 and IL13 induced the shift from type I 
BL and EBV positive HL cell lines to type IIa latency, while IL21 induced a switch from 
latency III to IIa. Based on these findings we studied the plausible role of activated CD4+ T 
cells in altering EBV gene expression pattern. 
Activated CD4+ T cells co-cultured with autologous or allogenic LCLs downregulated 
EBNA2 expression, indicating a shift from latency III towards latency IIa. Downregulation of 
EBNA2 was accompanied by the concomitant decrease in proliferation. The co-culture 
system does not corroborate whether EBNA2 downregulation was CD4+ T cell contact 
dependent or not. In order to address this, the transwell (TW) experimental system was 
exploited, where the LCLs were confined to the insert and the activated CD4+ T cell were 
cultured at the bottom of the well. Similar to the co-culture, activated CD4+ T cells in the TW 
system downregulated EBNA2 expression, but upregulated LMP1. This phenomenon was not 
observed with CD8+ T cells. Decrease in EBNA2 was accompanied by the decrease in 
CD23, a B cell activation marker upregulated in cells with latency III. The changes in 
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EBNA2 and LMP1 expression were also confirmed at the transcriptional level. The decrease 
in EBNA2 mRNA transcripts correlated with decreased Cp activity, suggesting a switch from 
latency III viral program. However, Qp activity remained unchanged, indicating only a partial 
switch to latency IIa. 
Based on our previous knowledge that IL21 negatively regulates EBNA2 and positively 
regulates LMP1 [246], neutralizing anti IL21 was added to the TW system. Functional 
inhibition of IL21 in TW experiments decreased LMP1 expression, but did not restore 
expression of EBNA2 to its initial level. This suggested that IL21 was only accountable for 
the upregulation of LMP1, and other soluble factor/s were involved in the regulation of 
EBNA2. 
Based on an earlier finding that CD40L can downregulate EBNA2 expression in LCLs [247], 
neutralizing anti-CD40 antibody was introduced in the TW experiments. Partial inhibition of 
EBNA2 expression was achieved with this treatment. Thus, we demonstrate the role of 
soluble factors secreted by CD4+ T cells in regulating EBV latency switch from type III to II. 
 
Interferon γ induces BCL6 expression in multiple myeloma and in imatinib treated 
chronic myeloid leukemia cells through STAT1 (Paper IV) 
BCL6 is a transcriptional factor essential for the normal development of T and B 
lymphocytes. Deregulation of BCL6 expression is strongly associated with the pathogenesis 
of several hematological malignancies such as, DLBCL, BL and MM. Also, BCL6 
expression is essential for the survival of Ph positive CML stem cells resisting IM treatment. 
It has been reported that T cells in IM treated CML patients secrete increased levels of INFγ 
[185]. In addition, INFγ has been reported to modulate the response of CML cells to TKIs 
treatment. Based on earlier reports of BCL6 induction through INFγ signaling in T cells and 
keratinocytes [248-250], we investigated the plausibility of INFγ induced BCL6 expression in 
MM and CML cells. 
To this end, BCL6 expression was tested in MM, CML and IM treated CML cells following 
the treatment with several well characterized growth/survival factors. Rapid and strong 
induction of BCL6 mRNA was observed in MM and IM treated CML cell treated with INFγ. 
Both variants of BCL6 mRNA were induced upon INFγ treatment, suggesting that both 
regions A and B on the BCL6 promoter are activated. Induction of BCL6 was independent of 
de novo protein synthesis. 
INFγ activates several pathways besides the classical JAK/STAT1 signaling pathway. 
However, only STAT1 was phosphorylated following INFγ treatment in untreated and IM 
treated CML cells. IM inhibited BCR-ABL mediated constitutive phosphorylation of STAT5 
in CML cells, untreated or treated with INFγ. From our observations in CML cells, INFγ 
induced BCL6 expression was restricted only to cells treated with IM, which rendered 
STAT5 inactive. It has been shown that STAT5 displays a dual effect on gene regulation, 
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inducing or repressing transcription of target genes. STAT5 homodimer binds to specific 
DNA motifs initiating transcription, whereas STAT5 tetrameric complex can also bind to 
STAT5 specific binding sites, but in this instance repress transcription [251]. Tetrameric 
STAT5 complexes interact with histone H3 Lys27 (H3K27) methylase Ezh2, forming a 
H3K27-trimethylated repressive chromatin [252]. This suggested that the constitutive 
phosphorylated STAT5 might have an inhibitory effect on BCL6 transcription in CML cells 
not treated with IM. Specific inhibition of STAT5 in CML cells treated with INFγ alone 
induced strong BCL6, without affecting transcription of IRF1. This also suggested the 
dominant repressive role of pSTAT5 regulation of BCL6 in CML cells treated with INFγ. As 
a next step, Ph positive stem cells were isolated from peripheral blood of untreated CML 
patients to examine BCL6 expression following INFγ and IM treatment. BCL6 transcription 
was induced only in CML stem cells treated with combination of INFγ and IM. However 
transcription of IRF1 increased with INFγ treatment, not affected by the presence or absence 
of IM. 
Similarly to the effect of INFγ on CML cells, STAT1 was phosphorylated, in INFγ treated 
MM cells. However, INFα treatment of these cells induced a much stronger STAT1 
phosphorylation than INFγ, but also very strong STAT5 phosphorylation accompanied by the 
lack in BCL6 expression. Based on the earlier finding of the dominant repressive inhibition 
effect of STAT5 over STAT1 in CML cells, downregulation of STAT5 by siRNA in MM 
cells treated with INFα induced strong BCL6 transcription. Expression of ISG56 was 
unaltered with the downregulation of STAT5. This confirmed STAT5’s dominant repressive 
effect on BCL6 expression also in MM cells. 
Our finding suggests that INFγ through STAT1 induces BCL6, an oncogenic master regulator 
critical for the survival of MM and IM treated CML stem cells. 
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